Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;146(5):767-770.
doi: 10.1007/s00401-023-02623-8. Epub 2023 Aug 19.

TDP-43 pathology in the retina of patients with frontotemporal lobar degeneration

Anke A Dijkstra  1   2 , Tjado H J Morrema  3 , Frederique J Hart de Ruyter  3   4 , Priya Gami-Patel  3 , Frank D Verbraak  5 , Johannes F de Boer  6 , Femke H Bouwman  4 , Yolande A L Pijnenburg  4 , Jurre den Haan  4 , Annemieke J Rozemuller  3 , Jeroen J M Hoozemans  3
Affiliations

TDP-43 pathology in the retina of patients with frontotemporal lobar degeneration

Anke A Dijkstra et al. Acta Neuropathol. 2023 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: Anke A. Dijkstra, Tjado H. J. Morrema, Frederique Hart-de Ruijter, Priya Gami-Patel, Frank D. Verbraak, Jurre den Haan, and Annemieke J. Rozemuller report no competing interests; Prof. dr. J. F. de Boer has acquired grant support (for the institution; Department of Physics, VU) from the Dutch Research Council (NWO) and from industry (Thorlabs, ASML, Heidelberg Engineering). He has received royalties related to IP on OCT technologies and semiconductor metrology. He has acted as an expert witness for a UK-based law firm; Dr. F. Bouwman performs contract research for Optina Dx and Optos, she has been an invited speaker at Roche and has been invited for expert testimony at Biogen. All funding is paid to her institution; Dr. J. J. M. Hoozemans received grants from the Dutch Research Council (ZonMW) and, Alzheimer Netherlands, performed contract research or received grants from Merck, ONO Pharmaceuticals, Janssen Prevention Center, DiscovericBio, AxonNeurosciences, Roche, Genentech, Promis, Denali, First Biotherapeutics, and Ensol Biosciences. All payments were made to the institution. Dr. J. J. M. Hoozemans participates in the scientific advisory board of Alzheimer Netherlands and is editor-in-chief for Acta Neuropathologica Communications. Ethical approval: Prior to death donors signed informed consent for brain and eye autopsy and use of brain and eye tissue as well as medical records for research activities. This study was approved by the medical ethical committee of the VUmc (reference# 2009/148).

Figures

Fig. 1
Fig. 1
Pathological features of FTLD-TDP are present in the retina. a–g pTDP-43 immunostaining in the frontal cortex shows the typical distribution specific for FTLD-TDP subtypes. a′–g′ pTDP-43 immunoreactive aggregates are observed in the outer plexiform layer (OPL) in FTLD-TDP cases. a″–g″ Aggregates in the OPL are observed with panTDP immunostaining. a′′′–d′′′ In C9orf72 hexanucleotide repeat expansion carriers P62 immunostaining shows larger aggregates in the OPL, and small aggregates in the inner nuclear layer (INL). a″″–d″″ PolyGA immunoreactive aggregates are observed in the INL in C9orf72 hexanucleotide repeat expansion carriers. Scale bar: 20 µm (applicable to all images), scale bar inserts: 10 µm (applicable to all inserts). Immunostaining shown with DAB (brown) and nuclei are counterstained with hematoxylin (blue). h, i Fluorescent double-immunostainings for pTDP-43 (green) with calbindin D28K and calretinin. h shows presence of calretinin (red) in amacrine cells in the INL and its processes in the IPL. i shows detection of calbindin D28K (red) in cones, horizontal cells and bipolar cells. Scale bar: 50 µm (applicable to both images). Nuclear staining with DAPI (blue)
See this image and copyright information in PMC

References

    1. Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20–38. doi: 10.1002/ana.23937. - DOI - PMC - PubMed
    1. Fawzi AA, Simonett JM, Purta P, Moss HE, Lowry JL, Deng HX, et al. Clinicopathologic report of ocular involvement in ALS patients with C9orf72 mutation. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:569–580. doi: 10.3109/21678421.2014.951941. - DOI - PMC - PubMed
    1. Goodwill VDC, Chea L, Sigurdson C, Alvarez V, McKee A, Lin J (2020) Chronic traumatic encephalopathy is associated with TDP-43 retinal pathology. https://iovs.arvojournals.org/article.aspx?articleid=2768896
    1. Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Serie AM, Perkerson RB, et al. Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathol. 2019;137:227–238. doi: 10.1007/s00401-018-1951-7. - DOI - PMC - PubMed
    1. Koronyo Y, Rentsendorj A, Mirzaei N, Regis GC, Sheyn J, Shi H, et al. Retinal pathological features and proteome signatures of Alzheimer's disease. Acta Neuropathol. 2023;145:409–438. doi: 10.1007/s00401-023-02548-2. - DOI - PMC - PubMed

LinkOut - more resources